L. T. Toguzaeva

L. T. Toguzaeva

Auto-generated profile, based on publicly available information

L. T. Toguzaeva

Academician Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Health Ministry of Russian Federation

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2025 in Медицинский оппонент
Verified
Journal Article
Closed access
ЯГЯ.о. Габуева
Я.о. Габуева
ЛТЛ.т. Тогузаева
Л.т. Тогузаева
ДОД.л. Оводенко
Д.л. Оводенко
АГА.а. Горпенко
А.а. Горпенко
ВЧВ.д. Чупрынин
В.д. Чупрынин
НБН.а. Буралкина
Н.а. Буралкина
Рак шейки матки представляет собой одну из ключевых проблем в онкогинекологии, так как обусловлен высокой заболеваемостью, смертностью, а также значительным влиянием на качество жизни пациенток. Помимо угрозы для жизни, заболевание и его лечение приводят к выраженным психоэмоциональным нарушениям и сексуальной дисфункции. Целью исследования являлось изучить качество жизни и сексуальную функцию женщин до и после проведения радикального хирургического лечения по поводу рака шейки матки.

10 January 2025 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
ESEkaterina V. Slukhanchuk
Ekaterina V. Slukhanchuk
VBVictoria Bitsadze
Victoria Bitsadze
ASA. G. Solopova
A. G. Solopova
JKJamilya Khizroeva
Jamilya Khizroeva
KGK. N. Grigoreva
K. N. Grigoreva
AMAlexander Makatsariya
Alexander Makatsariya
Cancer patients are at risk of developing arterial and venous thrombosis during chemotherapy (CT) and after its cessation. A prothrombotic risk may arise via pathogenetic pathways such as activation of external and internal coagulation pathways, decreased anticoagulant levels, platelet activation, fibrinolysis blockade, etc. Chemotherapeutic agents exert direct cytotoxicity, as well as indirectly suppress cellular processes necessary for tumor cell proliferation. CT-related cytotoxicity act on both tumor and healthy body cells. Available targeted drugs with improved selectivity for tumor cells are also associated with thrombosis risk. Low molecular weight heparins, which effectively reduce the risk of venous thromboembolism, have not yet been officially recommended for routine use during CT. Here, we discuss the prothrombotic effects of various antitumor agents aimed at gaining deeper understanding of the underlying mechanisms that may allow to develop new strategies for prevention and treatment of such formidable complications.